DVHGF (Devonian Health Group) ROCE %: -102.27% (As of Jan. 2026)

What is Devonian Health Group ROCE %?

Devonian Health Group DVHGF 49 ROCE % is -102.27% as of Jan. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Devonian Health Group's annualized ROCE % for the quarter that ended in Jan. 2026 was -102.27%.

Devonian Health Group (OTCPK:DVHGF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Devonian Health Group ROCE % Related Terms

Devonian Health Group ROCE % Historical Data

* Premium members only.

The historical data trend for Devonian Health Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group ROCE % Chart

Devonian Health Group Annual Data

Trend

Jun16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Jul25

ROCE %

Get a 7-Day Free Trial

-20.14

-15.21

-23.96

-4.23

-47.03

Devonian Health Group Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26
ROCE %	Get a 7-Day Free Trial															7.10	-1.05	-17.20	-65.27	-102.27

49GF Score

Devonian Health Group Inc DVHGF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Devonian Health Group ROCE % Calculation

Devonian Health Group's annualized ROCE % for the fiscal year that ended in Jul. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2025 )		(A: Jul. 2024 )		(A: Jul. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2025 )		(A: Jul. 2024 )		(A: Jul. 2025 )
	=	-3.981	/	( ( (22.41 - 12.212)	+	(11.562 - 4.831) )	/ 2 )
	=	-3.981	/	( (10.198	+	6.731)	/ 2 )
	=	-3.981	/	8.4645
	=	-47.03 %

Devonian Health Group's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2026 )		(Q: Oct. 2025 )		(Q: Jan. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2026 )		(Q: Oct. 2025 )		(Q: Jan. 2026 )
	=	-6.496	/	( ( (11.132 - 4.221)	+	(6.947 - 1.154) )	/ 2 )
	=	-6.496	/	( ( 6.911	+	5.793 )	/ 2 )
	=	-6.496	/	6.352
	=	-102.27 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -102.27% mean?

Devonian Health Group (DVHGF) has a ROCE % of -102.27% as of Jan. 2026.

Is Devonian Health Group's ROCE % too high?

Devonian Health Group's current ROCE % is -102.27%. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Devonian Health Group's ROCE % compare to VRTX and REGN?

Devonian Health Group's ROCE % of -102.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Devonian Health Group's current ROCE % is -102.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Devonian Health Group stock overvalued right now?

Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current ROCE % is -102.27%. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current ROCE % is -102.27% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devonian Health Group (DVHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued. The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02. GuruFocus considers Devonian Health Group to be Significantly Overvalued.

Key valuation signals for DVHGF:

ROCE %: -102.27%
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devonian Health Group Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:LOBE XCNQ:BETR TSXV:TTI TSX:RVX TSXV:SHRX TSXV:ALZI TSX:MDNA XCNQ:QNTM XCNQ:MDMA TSX:BCT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges GSD:Canada

Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1

Website https://www.groupedevonian.com

Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.

49GF Score

Get the complete analysis for DVHGF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00

Price

$3.02

GF Value

View DVHGF Analysis

See ROCE % data for all stocks →